Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder

Shaji Abraham, Deborah W. Knapp, Liang Cheng, Paul W. Snyder, Suresh K. Mittal, Dinesh S. Bangari, Michael Kinch, Lan Wu, Jay Dhariwal, Sulma I. Mohammed

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Purpose: The EphA2 receptor tyrosine kinase is believed to play a role in tumor growth and metastasis. The clinical significance of the expression of EphA2 was observed in breast, prostate, colon, skin, cervical, ovarian, and lung cancers. The purpose of this work was to determine the expression of EphA2 and its ligand, Ephrin A-1, and E-cadherin in carcinoma of the urinary bladder, and determine EphA2 as a new target for therapy in bladder cancer. Experimental Design: EphA2 mRNA and protein expression was investigated by reverse transcription-PCR and Western blot, respectively, in bladder cancer cell lines. In addition, the expression of EphA2, Ephrin A-1, and E-cadherin in tissues from patients with different stages of urinary bladder cancer was determined by immunohistochemistry. Furthermore, the ability of Ephrin A-1 to inhibit growth of bladder cancer cells was also investigated using an adenoviral delivery system. Results: Western blot analysis showed high EphA2 expression in TCCSUP, T24, and UMUC-3 cell lines. In tissues, the staining intensity of EphA2 was less in normal urothelium but increased greatly in advancing stages of urothelial carcinoma (P < 0.05). Similarly, the staining intensity of Ephrin A-1 was low in normal tissues and high in cancerous tissues, but it was similar across the various stages of urothelial carcinoma (Ta-T4). E-cadherin immunoreactivity decreased in urothelial cancer. Association of EphA2 and Ephrin A-1 expression was found to be significant between Ta stage and T1-T2 (P < 0.04) and Ta and T 3-T4 stages (P < 0.0001). Adenovirus delivery of Ephrin A-1 inhibited proliferation of TCCSUP cells. Conclusion: EphA2 may serve as a novel target for bladder cancer therapy.

Original languageEnglish
Pages (from-to)353-360
Number of pages8
JournalClinical Cancer Research
Volume12
Issue number2
DOIs
StatePublished - Jan 15 2006

Fingerprint

Ephrins
Urinary Bladder
Urinary Bladder Neoplasms
Carcinoma
EphA2 Receptor
Cadherins
Western Blotting
Staining and Labeling
Cell Line
Urothelium
Skin Neoplasms
Growth
Adenoviridae
Uterine Cervical Neoplasms
Ovarian Neoplasms
Colonic Neoplasms
Reverse Transcription
Lung Neoplasms
Neoplasms
Prostatic Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Abraham, S., Knapp, D. W., Cheng, L., Snyder, P. W., Mittal, S. K., Bangari, D. S., ... Mohammed, S. I. (2006). Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clinical Cancer Research, 12(2), 353-360. https://doi.org/10.1158/1078-0432.CCR-05-1505

Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. / Abraham, Shaji; Knapp, Deborah W.; Cheng, Liang; Snyder, Paul W.; Mittal, Suresh K.; Bangari, Dinesh S.; Kinch, Michael; Wu, Lan; Dhariwal, Jay; Mohammed, Sulma I.

In: Clinical Cancer Research, Vol. 12, No. 2, 15.01.2006, p. 353-360.

Research output: Contribution to journalArticle

Abraham, S, Knapp, DW, Cheng, L, Snyder, PW, Mittal, SK, Bangari, DS, Kinch, M, Wu, L, Dhariwal, J & Mohammed, SI 2006, 'Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder', Clinical Cancer Research, vol. 12, no. 2, pp. 353-360. https://doi.org/10.1158/1078-0432.CCR-05-1505
Abraham, Shaji ; Knapp, Deborah W. ; Cheng, Liang ; Snyder, Paul W. ; Mittal, Suresh K. ; Bangari, Dinesh S. ; Kinch, Michael ; Wu, Lan ; Dhariwal, Jay ; Mohammed, Sulma I. / Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. In: Clinical Cancer Research. 2006 ; Vol. 12, No. 2. pp. 353-360.
@article{0ea805b2846d47babb2d44c1fa1b31de,
title = "Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder",
abstract = "Purpose: The EphA2 receptor tyrosine kinase is believed to play a role in tumor growth and metastasis. The clinical significance of the expression of EphA2 was observed in breast, prostate, colon, skin, cervical, ovarian, and lung cancers. The purpose of this work was to determine the expression of EphA2 and its ligand, Ephrin A-1, and E-cadherin in carcinoma of the urinary bladder, and determine EphA2 as a new target for therapy in bladder cancer. Experimental Design: EphA2 mRNA and protein expression was investigated by reverse transcription-PCR and Western blot, respectively, in bladder cancer cell lines. In addition, the expression of EphA2, Ephrin A-1, and E-cadherin in tissues from patients with different stages of urinary bladder cancer was determined by immunohistochemistry. Furthermore, the ability of Ephrin A-1 to inhibit growth of bladder cancer cells was also investigated using an adenoviral delivery system. Results: Western blot analysis showed high EphA2 expression in TCCSUP, T24, and UMUC-3 cell lines. In tissues, the staining intensity of EphA2 was less in normal urothelium but increased greatly in advancing stages of urothelial carcinoma (P < 0.05). Similarly, the staining intensity of Ephrin A-1 was low in normal tissues and high in cancerous tissues, but it was similar across the various stages of urothelial carcinoma (Ta-T4). E-cadherin immunoreactivity decreased in urothelial cancer. Association of EphA2 and Ephrin A-1 expression was found to be significant between Ta stage and T1-T2 (P < 0.04) and Ta and T 3-T4 stages (P < 0.0001). Adenovirus delivery of Ephrin A-1 inhibited proliferation of TCCSUP cells. Conclusion: EphA2 may serve as a novel target for bladder cancer therapy.",
author = "Shaji Abraham and Knapp, {Deborah W.} and Liang Cheng and Snyder, {Paul W.} and Mittal, {Suresh K.} and Bangari, {Dinesh S.} and Michael Kinch and Lan Wu and Jay Dhariwal and Mohammed, {Sulma I.}",
year = "2006",
month = "1",
day = "15",
doi = "10.1158/1078-0432.CCR-05-1505",
language = "English",
volume = "12",
pages = "353--360",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder

AU - Abraham, Shaji

AU - Knapp, Deborah W.

AU - Cheng, Liang

AU - Snyder, Paul W.

AU - Mittal, Suresh K.

AU - Bangari, Dinesh S.

AU - Kinch, Michael

AU - Wu, Lan

AU - Dhariwal, Jay

AU - Mohammed, Sulma I.

PY - 2006/1/15

Y1 - 2006/1/15

N2 - Purpose: The EphA2 receptor tyrosine kinase is believed to play a role in tumor growth and metastasis. The clinical significance of the expression of EphA2 was observed in breast, prostate, colon, skin, cervical, ovarian, and lung cancers. The purpose of this work was to determine the expression of EphA2 and its ligand, Ephrin A-1, and E-cadherin in carcinoma of the urinary bladder, and determine EphA2 as a new target for therapy in bladder cancer. Experimental Design: EphA2 mRNA and protein expression was investigated by reverse transcription-PCR and Western blot, respectively, in bladder cancer cell lines. In addition, the expression of EphA2, Ephrin A-1, and E-cadherin in tissues from patients with different stages of urinary bladder cancer was determined by immunohistochemistry. Furthermore, the ability of Ephrin A-1 to inhibit growth of bladder cancer cells was also investigated using an adenoviral delivery system. Results: Western blot analysis showed high EphA2 expression in TCCSUP, T24, and UMUC-3 cell lines. In tissues, the staining intensity of EphA2 was less in normal urothelium but increased greatly in advancing stages of urothelial carcinoma (P < 0.05). Similarly, the staining intensity of Ephrin A-1 was low in normal tissues and high in cancerous tissues, but it was similar across the various stages of urothelial carcinoma (Ta-T4). E-cadherin immunoreactivity decreased in urothelial cancer. Association of EphA2 and Ephrin A-1 expression was found to be significant between Ta stage and T1-T2 (P < 0.04) and Ta and T 3-T4 stages (P < 0.0001). Adenovirus delivery of Ephrin A-1 inhibited proliferation of TCCSUP cells. Conclusion: EphA2 may serve as a novel target for bladder cancer therapy.

AB - Purpose: The EphA2 receptor tyrosine kinase is believed to play a role in tumor growth and metastasis. The clinical significance of the expression of EphA2 was observed in breast, prostate, colon, skin, cervical, ovarian, and lung cancers. The purpose of this work was to determine the expression of EphA2 and its ligand, Ephrin A-1, and E-cadherin in carcinoma of the urinary bladder, and determine EphA2 as a new target for therapy in bladder cancer. Experimental Design: EphA2 mRNA and protein expression was investigated by reverse transcription-PCR and Western blot, respectively, in bladder cancer cell lines. In addition, the expression of EphA2, Ephrin A-1, and E-cadherin in tissues from patients with different stages of urinary bladder cancer was determined by immunohistochemistry. Furthermore, the ability of Ephrin A-1 to inhibit growth of bladder cancer cells was also investigated using an adenoviral delivery system. Results: Western blot analysis showed high EphA2 expression in TCCSUP, T24, and UMUC-3 cell lines. In tissues, the staining intensity of EphA2 was less in normal urothelium but increased greatly in advancing stages of urothelial carcinoma (P < 0.05). Similarly, the staining intensity of Ephrin A-1 was low in normal tissues and high in cancerous tissues, but it was similar across the various stages of urothelial carcinoma (Ta-T4). E-cadherin immunoreactivity decreased in urothelial cancer. Association of EphA2 and Ephrin A-1 expression was found to be significant between Ta stage and T1-T2 (P < 0.04) and Ta and T 3-T4 stages (P < 0.0001). Adenovirus delivery of Ephrin A-1 inhibited proliferation of TCCSUP cells. Conclusion: EphA2 may serve as a novel target for bladder cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=31544478574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31544478574&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-05-1505

DO - 10.1158/1078-0432.CCR-05-1505

M3 - Article

C2 - 16428472

AN - SCOPUS:31544478574

VL - 12

SP - 353

EP - 360

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2

ER -